Suncrest_GA45977 - evaluate the efficacy of RO7837195 compared with placebo in inducing remission
Research type
Research Study
Full title
A PHASE IIb, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION STUDY WITH AN ACTIVE TREATMENT EXTENSION TO ASSESS THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF RO7837195 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
IRAS ID
1012418
Contact name
Tracy Ogbunamiri
Contact email
Sponsor organisation
Genentech, Inc.
Clinicaltrials.gov Identifier
NCT06979336
Research summary
The purpose of this study is to compare the effects, good or bad, of different doses of RO7837195 versus placebo on patients with ulcerative colitis. This study has three parts: 1. Screening 2. Treatment 3. Follow-up
Over the treatment period, patients will receive either RO7837195 or placebo, as indicated below:
• RO7837195, given on Day 1 as an infusion (into the vein) over about 1 hour, then as an injection once a month (starting at Week 4) for 12 months
• Placebo, given on Day 1 as an infusion over about 1 hour, then as an injection once a month (starting at Week 4) for 2 months.
Thereafter, placebo will switch to RO7837195, given as an injection once a month for 10 months. A placebo looks like a drug but has no active ingredient.
During this study, patients will have visits approximately every 4 weeks while they are receiving treatment. Patients will also have two follow-up visits at 4 weeks and 17 weeks after final dose of study treatment. Visits may last 2-6 hours. Total time in the study for patients will be about 16 months. About 224 people will take part in this study.
Genentech, Inc. (a member of the Roche Group) is the sponsor of this study.REC name
West Midlands - Edgbaston Research Ethics Committee
REC reference
25/WM/0143
Date of REC Opinion
19 Aug 2025
REC opinion
Further Information Favourable Opinion